Skip to main content
Clinical Trials/NCT04692909
NCT04692909
Unknown
Not Applicable

Deep Transcranial Magnetic Stimulation (dTMS) of the Medial Prefrontal Cortex (mPFC) in Food Addiction and Obesity

Soroka University Medical Center1 site in 1 country24 target enrollmentJanuary 15, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Food Addiction
Sponsor
Soroka University Medical Center
Enrollment
24
Locations
1
Primary Endpoint
Change in BMI
Last Updated
5 years ago

Overview

Brief Summary

This experiment is based on a unique technique of deep Transcranial magnetic stimulation (dTMS) of the brain's cortex, aiming to produce weight loss in food-addicted severely obese adults.

Detailed Description

The neurobiological underpinnings of food addiction in obesity point to chemical, structural and functional imbalance in the mesolimbic dopaminergic brain system. This may cause symptoms of altered reward processing, excessive cravings for hyperpalatable food and repeated self-regulation failures to control food intake in this population. Specifically, the medial prefrontal cortex (mPFC), anterior cingulate cortex (ACC) and deeper reward-related brain regions function differentially from healthy controls and similarly to individuals with substance or behavioral addiction. Deep transcranial magnetic stimulation of the mPFC has been shown efficacious in reducing cravings and other addictive symptoms in individuals with SUD, as well as symptoms of compulsivity in obsessive compulsive disorder (OCD). In this study the investigators use deep transcranial magnetic stimulation (dTMS) with an H-coil to safely stimulate the mPFC and deeper brain regions, in individuals with obesity and food addiction. The investigators aim to produce neuroplasticity favoring the restoration of mPFC functioning, alleviating food addiction symptoms and promoting weight loss.

Registry
clinicaltrials.gov
Start Date
January 15, 2021
End Date
December 1, 2022
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 30 ≤ BMI ≥
  • Having had at least one prior conventional weight loss attempt, but no current weight loss attempts or over the last 3 months.
  • Having satisfied a safety screening questionnaire for TMS (Keel, 2001)
  • Omnivorous
  • Have not had experience with TMS of any kind

Exclusion Criteria

  • They experience tremor in any limb.
  • They experience seizures.
  • They have a history of epilepsy or seizure (EXCEPT those therapeutically induced by ECT, or febrile childhood seizures).
  • They are at increased risk for seizures for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or a history of significant head trauma with loss of consciousness for \> 5 minutes.
  • A history of clinically significant neurological disorders, including organic brain disease, epilepsy, stroke, brain lesions, multiple sclerosis, previous neurosurgery or personal history of head trauma that resulted in loss of consciousness for \> 5 minutes and retrograde amnesia for \> 30 minutes (self-reported history).
  • They have a clinically significant hearing impairment, unless a medical letter is provided permitting the participant to receive a dTMS treatment.
  • The participant has an unstable physical disease, such as acute unstable cardiac disease, or high blood pressure (\>150 mmHg, systolic/\> 110 mmHg diastolic, unless a medical letter is provided permitting the participant to receive a dTMS treatment.
  • Exclusion criteria:
  • They experience tremor in any limb.
  • They experience seizures.

Outcomes

Primary Outcomes

Change in BMI

Time Frame: Change in BMI between baseline and follow-up (a month after day 15)

Unit of measure: BMI in kg/m\^2 (weight in kilograms, height in meters)

Secondary Outcomes

  • Eating behavior [restrictive eating (RE), emotional eating (EME), external eating (EXE)](The change in these parameters will be assessed between day 16 (a month after day 15) and baseline.)
  • Change in food addiction symptoms on the Yale Food Addiction Scale (YFAS)(The change in the number of symptoms on day 16 (a month after day 15) compared to baseline will be assessed.)
  • Cognitive regulation of eating(The change in reaction time on the Food Stroop task between day 16 (a month after day 15) and baseline.)
  • Quality of life(The change in the SF-36 score between baseline and day 16.)
  • Depressive symptoms(A change in BDI score from baseline to day 16.)
  • Eating behavior [cognitive restraint (CR), emotional eating (EE), uncontrollable eating (UE)] will be assessed with the Three Factor Eating Questionnaire (TFEQ).(The change in these parameters will be assessed between day 16 (a month after day 15) and baseline.)
  • Eating behavior [restrictive eating (RE), emotional eating (EME), external eating (EXE)] will be assessed with the Dutch Eating Behavior Questionnaire (DEBQ)(The change in these parameters will be assessed between baseline and day 15.)
  • Binge eating frequency(The change in binge eating frequency between baseline and day 16.)
  • General mood(The change in the overall score (positive affect minus negative affect) between baseline and day 16.)

Study Sites (1)

Loading locations...

Similar Trials